MétaCan
Menu
Back to cohort
Record W2967890583 · doi:10.1093/jac/dkz344

Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)

2019· article· en· W2967890583 on OpenAlexaff
Jon Salmanton‐García, Danila Seidel, Philipp Koehler, Sibylle C. Mellinghoff, Raoul Herbrecht, Н Н Климко, Zdeněk Ráčil, Iker Falces‐Romero, Paul R. Ingram, Miguel-Ángel Benítez-Peñuela, José Yesid Rodríguez, Guillaume Désoubeaux, Aleksandra Barać, Carolina García‐Vidal, Martin Hoenigl, Sanjay R. Mehta, Matthew P. Cheng, G. A. Klyasova, Werner Heinz, Nousheen Iqbal, Robert Krause, Helmut Ostermann, Olaf Penack, Enrico Schalk, Donald C. Sheppard, Birgit Willinger, Hilmar Wisplinghoff, Jörg Janne Vehreschild, Oliver A. Cornely, Reham Khedr, Alberto Arencibia-Núñez, Martha Avilés-Robles, Ingo J. Banke, Ariful Basher, Keertilaxmi Benachinamardi, H Bertz, Arunaloke Chakrabarti, Ľuboš Drgoňa, Jesús García‐Martínez, Julio García‐Rodríguez, Sandra Gräber, Georg Härter, Michael Klein, Michal Kouba, Dong‐Gun Lee, Yohann Le Govic, Fabian Leo, Johan Maertens, Georg Maschmeyer, Lisa Meintker, Xiao‐Dong Mo, Lena-Katharina Müller, N Müller, Jeremy Nel, J Novák, Atul Patel, Frieder Pfäfflin, Juan-Carlos Pozo-Laderas, Pedro Puerta-Alcalde, Azucena Rodríguez-Guardado, Roland Schroers, Vandana Shekar, Susan Shenoi, Gerda Silling, Donald C. Vinh, Salomón Waizel‐Haiat, Mandy Yap Yee Yee, Peralam Yegneswaran Prakash, Pavel Žák

Bibliographic record

VenueJournal of Antimicrobial Chemotherapy · 2019
Typearticle
Languageen
FieldMedicine
TopicAntifungal resistance and susceptibility
Canadian institutionsMcGill University Health Centre
FundersMerck
KeywordsPosaconazoleMucormycosisMedicineInternal medicineSurgeryDermatologyAntifungalAmphotericin B

Abstract

fetched live from OpenAlex

BACKGROUND: First-line antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B. Salvage treatment options are limited and often based on posaconazole oral suspension. With the approval of posaconazole new formulations, patients could benefit from improved pharmacokinetics, safety and tolerability. OBJECTIVES: Our aim was to assess the effectiveness of posaconazole new formulations for IM treatment. METHODS: We performed a case-matched analysis with proven or probable IM patients from the FungiScope® Registry. First-line posaconazole new formulations (1st-POSnew) and first-line amphotericin B plus posaconazole new formulations (1st-AMB+POSnew) cases were matched with first-line amphotericin B-based (1st-AMB) treatment controls. Salvage posaconazole new formulations (SAL-POSnew) cases were matched with salvage posaconazole oral suspension (SAL-POSsusp) controls. Each case was matched with up to three controls (based on severity, haematological/oncological malignancy, surgery and/or renal dysfunction). RESULTS: Five patients receiving 1st-POSnew, 18 receiving 1st-AMB+POSnew and 22 receiving SAL-POSnew were identified. By day 42, a favourable response was reported for 80.0% (n = 4/5) of patients receiving 1st-POSnew, for 27.8% (n = 5/18) receiving 1st-AMB+POSnew and for 50.0% (n = 11/22) receiving SAL-POSnew. Day 42 all-cause mortality of patients receiving posaconazole new formulations was lower compared with controls [20.0% (n = 1/5) in 1st-POSnew versus 53.3% (n = 8/15) in 1st-AMB; 33.3% (n = 6/18) in 1st-AMB+POSnew versus 52.0% (n = 26/50) in 1st-AMB; and 0.0% (n = 0/22) in SAL-POSnew versus 4.4% (n = 2/45) in SAL-POSsusp]. CONCLUSIONS: Posaconazole new formulations were effective in terms of treatment response and associated mortality of IM. While posaconazole new formulations may be an alternative for treatment of IM, the limited sample size of our study calls for a cautious interpretation of these observations.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.188
Threshold uncertainty score0.632

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.288
Teacher spread0.270 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations44
Published2019
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Antimicrobial ChemotherapySame topicAntifungal resistance and susceptibilityFrench-language works237,207